STOCK TITAN

COMPASS Pathways Plc American Depository Shares - CMPS STOCK NEWS

Welcome to our dedicated page for COMPASS Pathways Plc American Depository Shares news (Ticker: CMPS), a resource for investors and traders seeking the latest updates and insights on COMPASS Pathways Plc American Depository Shares stock.

Compass Pathways Plc (Nasdaq: CMPS) is a biotechnology company at the forefront of mental health innovation, dedicated to accelerating patient access to evidence-based therapies. Headquartered in London, UK, with offices in New York and San Francisco, Compass is pioneering a new model of psilocybin therapy, specifically targeting treatment-resistant depression (TRD). The company’s flagship product, a proprietary high-purity polymorphic crystalline formulation of synthetic psilocybin known as COMP360, is at the core of their therapeutic approach.

Compass Pathways has made significant strides in mental health care by combining psilocybin treatment with psychological support. This dual approach is designed to provide comprehensive care for patients unresponsive to standard treatments. COMP360 has been designated a 'Breakthrough Therapy' by the U.S. Food and Drug Administration (FDA) and also received the Innovative Licensing and Access Pathway (ILAP) designation in the UK for TRD.

The company's research is supported by robust clinical trials. Compass has commenced a Phase 3 clinical program for COMP360, making it the largest randomized, controlled, double-blind psilocybin treatment clinical program ever conducted. Previous Phase 2b studies have shown that a single 25mg dose of COMP360 can significantly improve depressive symptoms with sustained effects over weeks. In addition to TRD, Compass is exploring the potential of COMP360 for treating post-traumatic stress disorder (PTSD) and anorexia nervosa through ongoing Phase 2 clinical trials.

Recent collaborations with leading healthcare institutions like Hackensack Meridian Health and Journey Clinical are aimed at understanding and optimizing the delivery models for COMP360, should it receive FDA approval. These partnerships also include exploration into therapist training and care reimbursement processes to ensure that the treatment can be integrated smoothly into existing healthcare systems.

Financially, Compass Pathways remains committed to transparency and regular updates to investors through various platforms including their website, social media, and investor relations channels. The company's vision is to create a world where mental well-being is within reach for all.

For the latest news and updates on Compass Pathways, visit www.compasspathways.com.

Rhea-AI Summary

COMPASS Pathways (Nasdaq: CMPS) announced promising results from a recent study on COMP360 psilocybin therapy. In an exploratory open-label study for type II bipolar disorder, 86% of participants achieved remission within three months after a single 25mg dose. Additionally, data from a phase 2b trial for treatment-resistant depression (TRD) was presented, highlighting the correlation between positive psychedelic experiences and reduced depression severity. The therapy has received FDA Breakthrough Therapy designation, signaling its potential in mental health treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.24%
Tags
none
-
Rhea-AI Summary

LONDON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) will host a fireside chat at the Evercore ISI HealthCONx Conference at 9:15 am ET on November 30, 2022. A live audio webcast will be available on the COMPASS website's Events page, with a replay accessible for 30 days post-event. The company, focused on mental health innovation, is developing psilocybin therapy with its proprietary formulation, COMP360, which has received Breakthrough Therapy designation from the FDA for treatment-resistant depression. COMPASS also conducts trials for PTSD and anorexia nervosa.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.38%
Tags
conferences
-
Rhea-AI Summary

COMPASS Pathways (CMPS) has finalized the design for its Phase 3 pivotal program targeting treatment-resistant depression, set to commence in 2022. The Phase 2b trial data has been published in The New England Journal of Medicine, further validating the program. Financially, the company reported a net loss of $18.4 million for Q3 2022, up from $15.8 million in Q3 2021. Cash reserves stand at $173.1 million. Management remains optimistic as the COMP360 psilocybin therapy advances, with pivotal trial data expected in late 2024 and mid-2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.8%
Tags
Rhea-AI Summary

COMPASS Pathways (CMPS) announced positive results from its phase 2b trial of COMP360 psilocybin therapy for treatment-resistant depression (TRD), published in The New England Journal of Medicine. A single 25mg dose led to a remission rate of 29.1% at week 3, exceeding prior conventional treatments. Sustained response at week 12 was also notable, with 20.3% of patients remaining responsive. The company plans to initiate its phase 3 program by end of 2022, aiming to provide innovative treatment options for the 100 million globally affected by TRD.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.8%
Tags
-
Rhea-AI Summary

COMPASS Pathways (CMPS) announced key updates, including the appointment of Kabir Nath as CEO and the submission of Phase III protocols for COMP360 psilocybin therapy to the FDA. The Phase II study in anorexia nervosa has commenced, addressing a significant unmet medical need. Financially, the company reported a net loss of $21.0 million for Q2 2022, compared to $17.5 million in Q2 2021, with cash reserves of $207.2 million. R&D and G&A expenses increased due to higher headcount and consulting fees, signaling advancing development efforts.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.1%
Tags
-
Rhea-AI Summary

COMPASS Pathways plc (NASDAQ: CMPS) announced the grant of a non-qualified share option for 600,000 ordinary shares to their new CEO, Kabir Nath, as a material inducement for his employment. The option comes with an exercise price of $14.94, the closing price on the grant date, August 1, 2022. It vests over four years. Nath also received 50,000 restricted share units, vesting in equal annual installments. COMPASS focuses on psilocybin therapy for mental health challenges, with promising clinical trial results for treatment-resistant depression.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.82%
Tags
none
Rhea-AI Summary

COMPASS Pathways plc (Nasdaq: CMPS) has initiated a phase II clinical trial to evaluate the efficacy of COMP360 psilocybin therapy in treating anorexia nervosa, a condition currently lacking approved pharmacological solutions. The study will involve 60 participants at four leading research institutes in the UK and US, assessing the impact of two doses of psilocybin with psychological support over a 12-week period. This trial aims to address a critical unmet need, given the high mortality rates associated with anorexia.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.75%
Tags
-
Rhea-AI Summary

COMPASS Pathways plc (Nasdaq: CMPS) will release its financial results for Q2 2022 and provide updates on business developments on August 4, 2022. The management team will host a conference call at 8:00 AM ET, accessible via registration. The live webcast will also be available on the company's website and archived for 30 days.

COMPASS focuses on mental health innovations, particularly psilocybin therapy for treatment-resistant depression (TRD). Their proprietary formulation, COMP360, has received FDA Breakthrough Therapy designation, and positive results were reported from the largest psilocybin therapy clinical trial.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.95%
Tags
-
Rhea-AI Summary

COMPASS Pathways has appointed Kabir Nath as Chief Executive Officer effective August 1, 2022. He succeeds George Goldsmith, who will transition to Executive Chairman until the end of 2022. Nath brings extensive experience from Otsuka Pharmaceutical, focusing on mental health innovations. Goldsmith remains the Chairman, having overseen significant milestones including COMPASS’ IPO and the FDA designation for COMP360 psilocybin therapy aimed at treatment-resistant depression. The leadership shift aims to enhance patient access to innovative mental health care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.99%
Tags
management
Rhea-AI Summary

COMPASS Pathways plc (Nasdaq: CMPS) reported encouraging results from the largest phase IIb trial of COMP360 psilocybin therapy for treatment-resistant depression (TRD). Conducted with 233 patients, the study revealed that a single 25mg dose led to a significant reduction in depressive symptoms after three weeks (p<0.001), with lasting effects up to 12 weeks. Patients in the 25mg group showed a sustained response rate of 20.3% at week 12, compared to 10.1% in the 1mg group. The therapy was generally well-tolerated, with common mild side effects. The company aims to further investigate the therapy's efficacy in larger trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.95%
Tags
none

FAQ

What is the current stock price of COMPASS Pathways Plc American Depository Shares (CMPS)?

The current stock price of COMPASS Pathways Plc American Depository Shares (CMPS) is $3.97 as of December 20, 2024.

What is the market cap of COMPASS Pathways Plc American Depository Shares (CMPS)?

The market cap of COMPASS Pathways Plc American Depository Shares (CMPS) is approximately 275.7M.

What is Compass Pathways Plc?

Compass Pathways Plc is a biotechnology company focused on accelerating patient access to innovative mental health treatments, particularly using psilocybin therapy for treatment-resistant depression.

What is COMP360?

COMP360 is Compass Pathways' proprietary high-purity polymorphic crystalline formulation of synthetic psilocybin, used in conjunction with psychological support to treat mental health conditions like treatment-resistant depression.

What designations has COMP360 received?

COMP360 has been designated as a 'Breakthrough Therapy' by the FDA and received an Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment-resistant depression.

What clinical trials are currently underway for COMP360?

Compass Pathways has commenced Phase 3 clinical trials for COMP360 in treatment-resistant depression and is conducting Phase 2 studies for post-traumatic stress disorder (PTSD) and anorexia nervosa.

Who are Compass Pathways' partners in mental health research?

Compass Pathways has partnered with several institutions, including Hackensack Meridian Health and Journey Clinical, to improve the delivery and integration of COMP360 therapy into existing healthcare systems.

Where is Compass Pathways headquartered?

Compass Pathways is headquartered in London, UK, with additional offices in New York and San Francisco.

How does Compass Pathways communicate with its investors?

Compass Pathways regularly updates investors via their website, investor relations site, and social media platforms, providing access to press releases, SEC filings, and conference call webcasts.

What was the outcome of the Phase 2b study for COMP360?

The Phase 2b study showed that a single 25mg dose of COMP360 psilocybin resulted in a statistically significant and clinically relevant improvement in depressive symptoms after three weeks.

What is the focus of Compass Pathways' latest research collaborations?

The latest research collaborations focus on understanding patient pathways, therapist training, and the integration of COMP360 into healthcare delivery models to ensure effective and scalable treatment options.

What is the mission of Compass Pathways?

Compass Pathways aims to improve the lives of people suffering from mental health challenges through innovative, evidence-based therapies like psilocybin treatment.

COMPASS Pathways Plc American Depository Shares

Nasdaq:CMPS

CMPS Rankings

CMPS Stock Data

275.74M
53.27M
22.15%
48.37%
6.1%
Medical Care Facilities
Pharmaceutical Preparations
Link
United States of America
CHESIRE